Successful management of imatinib despite alopecia and nail necrosis
| dc.contributor.author | Ergene, U | |
| dc.contributor.author | Ozbalci, D | |
| dc.date.accessioned | 2024-07-18T11:53:53Z | |
| dc.date.available | 2024-07-18T11:53:53Z | |
| dc.description.abstract | Imatinib mesylate selectively inhibits bcr/abl and other non-specific tyrosine kinases, such as c-kit and platelet derived growth factor (PDGF) receptor and successfully used to treat chronic myeloid leukaemia (CML). In most cases, the drug is well tolerated: however, side effects can be seen. Hair loss and paronychia inflammation were often reported with Imatinib, but total alopecia was rarely mentioned. We report a CML patient who was presented with alopecia and paronychia inflammation probably induced by imatinib therapy. We have successfully treated our patient by cessation and then re-applying therapy with lower doses after improvement of lesions and have not found a similar report in literature. (C) 2013 Elsevier Ltd. All rights reserved. | |
| dc.identifier.issn | 1473-0502 | |
| dc.identifier.uri | http://akademikarsiv.cbu.edu.tr:4000/handle/123456789/5962 | |
| dc.language.iso | English | |
| dc.publisher | PERGAMON-ELSEVIER SCIENCE LTD | |
| dc.subject | SKIN | |
| dc.title | Successful management of imatinib despite alopecia and nail necrosis | |
| dc.type | Article |